Sun Pharma Faces Delhi HC Hurdle on Semaglutide Tablet Launch Amid Novo Patent Plea

The Delhi High Court has directed Sun Pharma Laboratories to seek its prior approval before commercially launching semaglutide tablets. The order follows Novo Nordisk’s patent infringement plea concerning the oral formulation of the diabetes and weight-management drug. The court asked Sun Pharma to inform and obtain clearance once it receives a commercial manufacturing licence, before any market rollout of the 3 mg, 7 mg and 14 mg strengths. *Top stocks in the pharmaceuticals industry:*

, Dr. Reddy’s Laboratories, and Lupin .